nChroma Bio formed by merging genetic medicine companies
The merger of Nvelop Therapeutics and Chroma Medicine brings together a combination of epigenetic editing and in vivo delivery expertise to develop new genetic medicines.
Mergers & deals
Roche acquires CAR-T developer Poseida Therapeutics for $1.5 billion
The acquisition will grant Roche full ownership over a pipeline of allogeneic CAR-T therapy candidates, including two oncology programs it had previously in-licensed.
AbbVie acquires Aliada Therapeutics in $1.4 billion deal
The acquisition of Aliada Therapeutics will grant AbbVie access to a neuroscience-focused technology platform and an Alzheimer's drug candidate originally developed by Johnson & Johnson.
Cellevate bags €3.2 million to smash viral vector manufacturing bottleneck
The Swedish biotech company Cellevate has raised €3.2 million in a seed round to fuel the commercialization of its nanofiber-based viral vector manufacturing technology in November.
Creyon Bio secures second patent for AI-powered oligonucleotide engineering
Creyon Bio Inc., a clinical-stage biotechnology company specializing in AI and machine learning-enabled oligonucleotide-based medicines (OBMs), recently announced the issuance of its second US patent.
Sangamo signs licensing agreement with Genentech worth up to $1.9 billion
The agreement will give Genentech access to Sangamo’s capsid delivery platform and epigenetic regulation technology with applications in neurodegenerative disease.
CVC Capital acquires immunomodulatory therapy business for $925 million
CVC Capital Partners has entered an agreement with specialty pharmaceutical company Mallinckrodt to acquire its Therakos business.
Bruker acquires stake in NovAliX, an alliance to revolutionize drug discovery
In a significant move set to reshape the landscape of drug discovery, NovAliX, a leading Contract Research Organization (CRO) specializing in drug development, has entered a strategic partnership with Bruker, a global leader in scientific instruments.
AIRNA raises $90 million Series A to bring RNA editing therapies to the clinic
AIRNA plans to bring RNA editing therapies to the clinic starting with a treatment for the genetic disease alpha-1 antitrypsin deficiency.